CanSinoBIO Rebrands to Reflect Its Commitment to Life Science Research


This is the first major renewal of the CanSinoBIO brand since its inception in 2009. The new logo retains the original core design using the double helix structure of DNA and reshapes it to add texture. The color blue represents “technology” and the color green represents “life”, embracing and complementing each other to describe the close relationship between technology and human life. In particular, the edge of the logo is softer than before, more clearly expressing care and consideration for all mankind.

The double helix was first introduced by Nature on April 25, 1953 as a groundbreaking discovery, and has since become a widely recognized symbol representing the code of life and the endless search and study of ourselves. Sixty-nine years later, CanSinoBIO continues to uphold the scientific spirit by engaging in continuous research and development (R&D) of innovative, high-quality and accessible vaccine products to protect human life.

Mission, vision and corporate values

With the launch of the new logo, CanSinoBIO’s corporate mission, vision and values ​​remain unchanged to continuously convey its corporate identity, representing the company’s adaptation to a rapidly changing business landscape, as well as its development strategy.

  • Mission: To provide the world with innovative, high quality and accessible vaccines
  • Vision: Innovating for a safer world
  • Corporate values: respect, agility, innovation, superior quality and commitment

Over the past thirteen years since its establishment, CanSinoBIO has achieved a significant number of milestones through its cutting-edge technology platforms and R&D, growing from a small team of four scientists in a single laboratory to a publicly listed company. with thousands of employees. globally.

The only recombinant Ebola vaccine in Asia the world’s first new recombinant coronavirus vaccine has entered clinical study, and China first and only MCV4 vaccine to the world’s first inhaled COVID-19 vaccine candidate, from building an mRNA technology platform to a number of the world’s leading vaccine products, CanSinoBIO has always been at the forefront of vaccine innovation, with a current robust portfolio of 17 vaccines preventing 12 diseases including COVID-19, meningococcal disease and Ebola.

So far, CanSinoBIO has built several smart vaccine production facilities in China international standard to ensure stable vaccine supply and jointly established advanced local filling and finishing facilities for efficient and safe supply and distribution in China, South East Asiathe Middle East and Latin Americaenabling access to quality vaccines to more people in developing markets.

Going forward, CanSinoBIO will continue to leverage the five integrated platform technologies to further diversify its vaccine portfolio and improve access to vaccines. The Company will expand collaboration with global innovators, upstream and downstream enterprises, to accelerate international cooperation.

Infectious diseases have plagued mankind throughout human history, and vaccinations are the most effective way to combat them. Each dose represents the painstaking aspiration and dedication of scientists and developers. CanSinoBIO is committed to protecting our future by providing innovative, high quality and accessible vaccines.

About CanSinoBIO

Incorporated in 2009, CanSinoBIO (SSE: 688185, HKEX: 06185) engages in the research, production and marketing of innovative vaccines for China and global health security. It has five integrated platform technologies, including viral vector-based technology, synthetic vaccine technology, protein structure design and recombinant technology, mRNA technology, as well as formulation technology. and administration. To date, it has established a strong portfolio of 17 vaccines preventing 12 diseases, including the new recombinant coronavirus vaccine (adenovirus type 5 vector) conditionally approved in 2021, the meningococcal group A and C conjugate vaccine ( CRM197) and the ACYW135 Meningococcal Conjugate Vaccine group (CRM197) approved the same year. Further information is available online at

SOURCE CanSino Biologics Inc.


Comments are closed.